Clinical trial
Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19).
NCT04414631 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19).
- Lead sponsor
- University Hospital, Basel, Switzerland
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- August 6, 2020
- Completion date
- September 15, 2021
- Enrollment
- 80 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.